SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (290)6/30/2000 11:35:02 AM
From: Skywatcher  Respond to of 328
 
Quite a turnaround from down 1 1/4 to up 1/2...guess many people really had some doubts about the drug, and pulling it for a better application will make the chances better for acceptance and less for rejection, which is what I think too many people thought would happen. Since the stock is now heading up...looks to be the case.
43 was a real ceiling for this one and now we have a bit of clearer sailing to the upside.
chris



To: Skywatcher who wrote (290)6/30/2000 9:02:36 PM
From: Frostman  Read Replies (2) | Respond to of 328
 
Chris, The deal between Abbott and Vivus is for Europe, Japan, etc. The FDA approval process and those of the countries that are involved are independent, but perhaps no less stringent. This set-back probably will not help over seas approval, but the door is not shut IMO.

Have a great holiday,

Frostman


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News